Micell's Optimism In MiStent Biosorbable Polymer Stent Grows With Retrospective Study
A retrospective propensity-matched comparison of Micell’s MiStent sirolimus-eluting absorbable polymer coronary stent system to Abbott’s popular Xience V everolimus-eluting stent suggests that MiStent has a good chance of outperforming Xience in the DESSOLVE III randomized trial.
You may also be interested in...
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.